Arrowhead Pharmaceuticals Inc. has signed a global licensing and collaboration agreement with Novartis for ARO-SNCA, a preclinical small interfering RNA (siRNA) therapy targeting alpha-synuclein for synucleinopathies, including Parkinson’s disease. The deal also includes additional collaboration targets leveraging Arrowhead’s proprietary Targeted RNAi Molecule (TRiM) platform. Under the terms, Arrowhead will receive a $200 million upfront payment and is eligible for up to $2 billion in milest...